Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Regulus Therapeutics (RGLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 127,871
  • Shares Outstanding, K 103,960
  • Annual Sales, $ 1,190 K
  • Annual Income, $ -81,840 K
  • 36-Month Beta 1.55
  • Price/Sales 1,065.90
  • Price/Cash Flow N/A
  • Price/Book 2.63
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.35
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/01/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    Medical - Drugs

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.89 +38.20%
on 12/15/17
1.31 -6.11%
on 01/08/18
+0.34 (+38.20%)
since 12/12/17
3-Month
0.85 +44.71%
on 11/30/17
1.35 -8.55%
on 10/17/17
-0.10 (-7.52%)
since 10/12/17
52-Week
0.79 +55.70%
on 08/21/17
2.60 -52.69%
on 01/13/17
-1.27 (-50.80%)
since 01/12/17

Most Recent Stories

More News
Biotech and Pain Management Therapeutics Segments Projected to Grow

According to EP Vantage, the editorial arm of Evaluate Ltd., in 2017 the FDA has given green light to 43 novel drugs, which are forecast to be generating a combined $32bn in US sales in five-years' time....

SBOT : 0.99 (+6.45%)
BICX : 0.2430 (+35.75%)
RGLS : 1.23 (+1.65%)
PTN : 0.90 (+3.56%)
PLX : 0.74 (+4.52%)
Analysis: Positioning to Benefit within Churchill Downs, Airgain, Fortune Brands Home & Security, Kemper, Perficient, and Regulus Therapeutics -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Churchill Downs, Incorporated...

CHDN : 252.85 (-0.28%)
AIRG : 9.27 (+0.76%)
PRFT : 19.62 (-1.41%)
FBHS : 70.62 (+1.20%)
KMPR : 69.60 (+1.31%)
RGLS : 1.23 (+1.65%)
Technical Perspectives on Argos Therapeutics, Omeros, Regulus Therapeutics, and Rhythm Pharma

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on ARGS, OMER, RGLS, and RYTM which can be accessed for free by signing up to www.wallstequities.com/registration....

ARGS : 0.16 (-3.03%)
RYTM : 27.40 (+1.67%)
RGLS : 1.23 (+1.65%)
OMER : 19.60 (-0.66%)
Regulus Announces First-in-Human Dosing for Phase I Study of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has initiated the first-in-human...

RGLS : 1.23 (+1.65%)
Regulus Reports Third Quarter 2017 Financial Results and Recent Events

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today summarized recent events and reported financial...

RGLS : 1.23 (+1.65%)
Regulus Therapeutics Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 7, 2017 / Regulus Therapeutics Inc. (NASDAQ: RGLS) will be discussing their earnings results in their Q3 Earnings Call to be held on November 7, 2017 at 5:00 PM Eastern...

RGLS : 1.23 (+1.65%)
Regulus to Provide Third Quarter 2017 Financial Results on November 7, 2017

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced it will provide third quarter 2017...

RGLS : 1.23 (+1.65%)
Regulus Therapeutics (RGLS) Looks Good: Stock Adds 5.6% in Session

Regulus Therapeutics Inc. (RGLS) was a big mover last session, as the company saw its shares rise nearly 6% on the day amid huge volumes

RGLS : 1.23 (+1.65%)
UCBJF : 81.4000 (+6.30%)
Regulus to Present at the 2017 Wells Fargo Healthcare Conference

Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan, President and Chief...

WFC : 62.55 (-0.73%)
RGLS : 1.23 (+1.65%)
Are Options Traders Betting on a Big Move in Regulus Therapeutics (RGLS) Stock?

Investors in Regulus Therapeutics Inc. (RGLS) need to pay close attention to the stock based on moves in the options market lately.

RGLS : 1.23 (+1.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

See More

Business Summary

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company's products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and...

See More

Key Turning Points

2nd Resistance Point 1.31
1st Resistance Point 1.27
Last Price 1.23
1st Support Level 1.19
2nd Support Level 1.16

See More

52-Week High 2.60
Fibonacci 61.8% 1.91
Fibonacci 50% 1.69
Fibonacci 38.2% 1.48
Last Price 1.23
52-Week Low 0.79

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.